Paclitaxel/carboplatin in the treatment of non-small-cell lung cancer

ONCOLOGY

Volumn 12, Issue 1 SUPPL. 2, 1998, Pages 74-79

  Belani, Chandra P ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN C; NAVELBINE; PACLITAXEL; VINBLASTINE; VINBLASTINE SULFATE; VINDESINE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FORECASTING; HUMANS; LUNG NEOPLASMS; PACLITAXEL;

EID: 0031915134     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 11:1866-1872, 1993.
2. Souquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non-small-cell lung cancer: A meta-analysis Lancet 342:19-21, 1993.
3. Eliis PA, Smith IE, Hardy JR, et al: Symptom relief with MVP (milomycin C. vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 71:366-370, 1995
4. Vogl SE, Bernzweig M, Camacho F, et al: Efficacy study of intensive cisplatin therapy in advanced non-small-cell bronchogenic carcinoma. Cancer 50:24-26, 1982.
5. Britell JC, Eagan RT, Ingle JN. et al. cis-Dichlorodiammineplatinum (II) alone followed by Adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum (II), Adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung. Cancer Treat Rep 62:1207-1210, 1978.
6. Casper ES, Gralla RJ, Kelsen DP, et al: Phase II study of high-dose cis-dichlorodiammineplatinum (II) in the treatment of non-smallcell lung cancer. Cancer Treat Rep 63:2107-2109, 1979.
7. Samson MK, Comis RL, Baker LH, et al: Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 62:163-165, 1978.
8. Costanzi JJ, Morgan LR, Hokanson J: Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung (suppl 1). Semin Oncol 9:61-65, 1982.
9. Morgan LR, Posey LE. Rainey J, et al: Ifosfamide: A weekly dose fractionated schedule in bronchogenic carcinoma. Cancer Treat Rep 65:693-695, 1981.
10. Harmon EF, Hawke JE, Hunter HL, et al: Single-dose ifosfamide: Efficacy studies in non-small-cell lung cancer (suppl 1). Semin Oncol 9:56-60, 1982.
11. Furnas BE, Williams SD, Einhorn LH, et al: Vindesine: An effective agent m the treatment of non-small-cell lung cancer. Cancer Treat Rep 66:1709-1711, 1982.
12. Luedke SL, Luedke DW, Petruska P. et al: Vindesine (VDS) monochemotherapy for non-small-cell lung cancer: A report of 45 cases. Cancer Treat Rep 66:1409-1411, 1982.
13. Schulman P, Budman DR, Vinciguerra V, et al: Phase II study of divided-dose vinblastine in non-small-cell bronchogenic carcinoma. Cancer Treat Rep 66:171-172, 1982.
14. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al: A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4:14-22, 1986
15. Bitran JD, Desser RK, DeMeester TR. et al: Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)-Effective four- drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma. Cancer Treat Rep 60:1225-1230, 1976
16. Ruckdeschel JC, Finkelstein DM. Mason B A, et al: Chemotherapy for metastatic non-smallcell bronchogenic carcinoma: EST 2575, GENERATION V - A randomized comparison of four cisplatin-containing regimens. J Clin Oncol 3:72-79, 1985
17. Eagan RT, Ingle JN, Frytak S, et al: Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small-cell lung cancer. Cancer Treat Rep 61:1339-1345, 1977.
18. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer -Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988.
19. Weick JK, Crowley S, Natale RB, et al: A randomized trial of five Cisplatin containing treatments in patients with metastatic non-small-cell lung cancer. A South West Oncology Group study. J Clin Oncol 9:1157-1162, 1991.
20. Mason BA, Catalano RB: Mitomycin. vinblastine and cisplatin combination chemotherapy in non-small-cell lung cancer (abstr). Proc Am Soc Clin Oncol 21:A477, 1980.
21. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613, 1989.
22. Bunn PA Jr Review of therapeutic trials of carboplatin in lung cancer(suppl 5). Semin Oncol 16:27-33, 1989.
23. Johnson DH, Paul DM, Hande KR, et al: Paclitaxel plus carboplatin in advanced non-smallcell lung cancer: A phase II trial. J Clin Oncol 14:2054-2060, 1996.
24. Calvert AH, Newell DR, Grumbell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1:1748-1756, 1989.
25. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Nat Cancer Insr 85:384-388, 1993.
26. Chang AY, Kim K, Click J. et al: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 85:388-394, 1993.
27. Gatzemeier U, Heckmayer M, Neuhauss R, et al: Chemotherapy of advanced inoperable non-small-cell lung cancer with paclitaxel: A phase II trial (suppl 5) Semin Oncol 22:24-28, 1995.
28. Millward MJ, Bishop JF, Friedlander M, et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer J Clin Oncol 14:142-148, 1996.
29. Ramanathan RK, Belani CP: Chemotherapy for advanced non-small-cell lung cancer: Past, present, and future. Semin Oncol 24:440-454, 1997.
30. Rowinsky EK, Citardi MJ, Noe DA, et al: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents Taxol and vincristine. J Cancer Res Clin Oncol 119:727-733, 1993.
31. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991.
32. Klastersky J, Sculier JP: Cisplatin plus taxol in non-small-cell lung cancer: A dose finding trial (abstr) Proc Am Assoc Cancer Res 36:A1423, 1995.
33. Pirker R, Krajnik G, Zochbauer S, et al: Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 6:833-835, 1995.
34. Belli L, Le Chevalier T, Gottfried M. et al: Phase HI trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non-small-cell lung cancer (NSCLC) (abstr). Proc Am Soc Clin Oncol 14:A1058, 1995.
35. Bonomi PD, Kim K, Chang A, et al: Phase III trial comparing etoposide (E) cisplatin versus Taxol (T) with cisplatin-G-CSF (G) versus cisplatin in advanced non-small-cell lung cancer: Eastern Cooperative Oncology Group (ECOG) (abstr). Proc Am Soc Clin Oncol 15:A1145, 1996.
36. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 13:1860-1870, 1995.
37. Belani CP, Aisner J, Hiponia D, et al: Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small-cell lung cancer (suppl 9). Semin Oncol 22:7-12, 1995.
38. Langer C, Kaplan R, Rosvold E, et al: Paclitaxel (P) by 1 hour (hr) infusion combined with carboplatin (C) in advanced non-small-cell lung carcinoma (abstr). Proc Am Soc Clin Oncol 15:A1200, 1996.
39. Vafai D, Israel V, Zaretsky S, et al: Phase I/II trial of combination carboplatin and Taxol in non-small-cell lung cancer (NSCLC) (abstr). Proc Am Soc Clin Oncol 14:A1067, 1995.
40. Bunn PA Jr, Kelly K: A phase I study of carboplatin and paclitaxel in non-small-cell lung cancer: A University of Colorado Cancer Center study (suppl 9). Semin Oncol 22:2-6, 1995.
41. Rowinsky EK, Sartonous SE, Bowling MK, et al: Paclitaxel on a 3-hr schedule and carboplatin in non-small-cell lung cancer: Use of maximally tolerated and clinically relevant single agent doses in combination is feasible (abstr). Proc Am Soc Clin Oncol 14:A1075, 1995.
42. Giaccone G, Huizing M, Postmus PE, et al: Dose-finding and sequencing study of paclitaxel and carboplatin in non-small-cell lung cancer (suppl 9). Semin Oncol 22:78-82, 1995.
43. Schutte W, Bork I, Sucker S: Phase II trial of paclitaxel and carboplatin as firstline treatment in advanced non-small-cell lung cancer (NSCLC) (abstr). Proc Am Soc Clin Oncol 15:A1208, 1996.
44. Roa V, Conner A, Mitchell RB: Carboplatin and paclitaxel for chemotherapy-naive patients with advanced non-small-cell lung cancer (abstr). Proc Am Soc Clin Oncol 15:A1231, 1996.
45. Evans WK, Stewart DJ, Tomiak E, et al: Carboplatin (C) and paclitaxel (P) by one hour infusion for advanced non-small-cell lung cancer (NSCLC) (abstr). Proc Am Soc Clin Oncol 14:A1156, 1996.
46. Kearns CM, Belani CP, Erkmen K, et al: Reduced platelet toxicity with combination carboplatin and paclitaxel; Pharmacodynamic modulation of carboplatin associated thrombocytopenia (abstr). Proc Am Soc Clin Oncol 14:A364, 1995.